Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer: A preliminary report
- 15 January 1983
- Vol. 51 (2) , 203-205
- https://doi.org/10.1002/1097-0142(19830115)51:2<203::aid-cncr2820510205>3.0.co;2-0
Abstract
Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin. Eleven patients (73%) responded with three complete and eight partial responses. The median duration of response was eight months. While all four nonresponders died within five months, the median duration of survival of responders was 18 months. Toxicity was significant but tolerable. Thus, this preliminary report suggests that this regimen is active in advanced previously treated breast cancer, providing meaningful remissions with acceptable toxicity.This publication has 3 references indexed in Scilit:
- One-day vath (vinblastine, adriamycin, thiotepa, and halotestin) therapy for advanced breast cancer refractory to chemotherapyCancer, 1981
- Vinblastine, adriamycin, thiotepa, and halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapyCancer, 1978
- Systemic Therapy for Metastatic Breast CancerAnnals of Internal Medicine, 1977